92 related articles for article (PubMed ID: 15791827)
1. [Effect of steroid on antiemetic for side effect of anticancer chemotherapy].
Nakamura Y; Momokawa K; Sasaki T; Sakayauchi T; Watanabe T; Mikami T; Matsumoto T
Gan To Kagaku Ryoho; 2005 Mar; 32(3):401-4. PubMed ID: 15791827
[TBL] [Abstract][Full Text] [Related]
2. The influence of dexamethasone in the decrease of chemotherapy-induced nausea and vomiting.
Sarcev T; Secen N; Povazan Dj; Sabo A; Popovic J; Bursac D; Kakas M; Zaric B; Milovancev A
J BUON; 2007; 12(2):245-52. PubMed ID: 17600880
[TBL] [Abstract][Full Text] [Related]
3. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
[TBL] [Abstract][Full Text] [Related]
4. [Management of nausea, vomiting and anorexia due to anticancer agents].
Shimada K; Taguchi S
Gan To Kagaku Ryoho; 2003 Jun; 30(6):760-4. PubMed ID: 12852341
[TBL] [Abstract][Full Text] [Related]
5. Management of platinum-based chemotherapy-induced acute nausea and vomiting: is there a superior serotonin receptor antagonist?
Hamadani M; Chaudhary L; Awan FT; Khan JK; Kojouri K; Ozer H; Tfayli A
J Oncol Pharm Pract; 2007 Jun; 13(2):69-75. PubMed ID: 17873106
[TBL] [Abstract][Full Text] [Related]
6. [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
Taguchi T; Tsukamoto F; Watanabe T; Yoneda K; Takamura Y; Hojo S; Shiba E; Noguchi S
Gan To Kagaku Ryoho; 1999 Jul; 26(8):1163-70. PubMed ID: 10431583
[TBL] [Abstract][Full Text] [Related]
7. Role of dexamethasone dosage in combination with 5-HT3 antagonists for prophylaxis of acute chemotherapy-induced nausea and vomiting.
Münstedt K; Müller H; Blauth-Eckmeyer E; Stenger K; Zygmunt M; Vahrson H
Br J Cancer; 1999 Feb; 79(3-4):637-9. PubMed ID: 10027342
[TBL] [Abstract][Full Text] [Related]
8. Antiemetic effect of ramosetron during hyperthermo-chemo-radiotherapy for esophageal cancer.
Morita M; Kuwano H; Ohno S; Kitamura K; Sugimachi K
Anticancer Res; 2000; 20(5C):3631-6. PubMed ID: 11268430
[TBL] [Abstract][Full Text] [Related]
9. [A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
Tanigaki Y; Mikami Y; Matsuda H; Horiuchi C; Taguchi T; Yoshida T; Ishitoya J; Katori H; Ikeda Y; Tsukuda M
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2091-5. PubMed ID: 16352934
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
[TBL] [Abstract][Full Text] [Related]
11. [Report of a case effectively treated by appropriate therapy for severe anticipatory nausea and vomiting due to FOLFOX or FOLFIRI].
Mori M; Kiba T; Oikawa M; Hokkoku K; Watanabe Y; Nakagawa T; Shintaku K; Yoshimitsu Y; Sakuma H; Ueda H; Nakai M
Gan To Kagaku Ryoho; 2009 Feb; 36(2):325-7. PubMed ID: 19223757
[TBL] [Abstract][Full Text] [Related]
12. [Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Miyashita M; Onda M; Ikeda K; Bando K; Hagiwara N; Tsuchiya Y; Yoshiyuki T; Kiyama T; Saito T; Sasajima K; Yamashita K
Gan To Kagaku Ryoho; 1999 Oct; 26(11):1629-35. PubMed ID: 10553422
[TBL] [Abstract][Full Text] [Related]
13. Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Lajolo PP; de Camargo B; del Giglio A
Am J Clin Oncol; 2009 Feb; 32(1):23-6. PubMed ID: 19194119
[TBL] [Abstract][Full Text] [Related]
14. 5-hydroxytryptamine type-3 receptor antagonists for chemotherapy-induced and radiotherapy-induced nausea and emesis: can we safely reduce the dose of administered agents?
Aapro M; Blower P
Cancer; 2005 Jul; 104(1):1-18. PubMed ID: 15929119
[TBL] [Abstract][Full Text] [Related]
15. [Nedaplatin (NDP)-combination therapy (NDP/5-FU,NDP/S-1) for oral cancer].
Maruoka Y; Ando T; Ogiuchi Y; Ogiuchi H
Gan To Kagaku Ryoho; 2007 May; 34(5):713-7. PubMed ID: 17496443
[TBL] [Abstract][Full Text] [Related]
16. Guidelines for the optimal management of chemotherapy-induced nausea and vomiting: a consensus.
Osoba D; Warr DG; Fitch MI; Nakashima L; Warren B
Can J Oncol; 1995 Sep; 5(3):381-400. PubMed ID: 8853513
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
[TBL] [Abstract][Full Text] [Related]
18. Clinical practice guidelines on antiemetics in oncology.
Aranda Aguilar E; Constenla Figueiras M; Cortes-Funes H; Diaz-Rubio García E; Gascon Vilaplana P; Guillém V; Martin-Algarra S
Expert Rev Anticancer Ther; 2005 Dec; 5(6):963-72. PubMed ID: 16336087
[TBL] [Abstract][Full Text] [Related]
19. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer.
Pinarli FG; Elli M; Dagdemir A; Baysal K; Acar S
Pediatr Blood Cancer; 2006 Oct; 47(5):567-71. PubMed ID: 16317736
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Sato Y; Takayama T; Sagawa T; Okamoto T; Miyanishi K; Sato T; Araki H; Iyama S; Abe S; Murase K; Takimoto R; Nagakura H; Hareyama M; Kato J; Niitsu Y
Cancer Chemother Pharmacol; 2006 Nov; 58(5):570-6. PubMed ID: 16463059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
